Science Explorer Back to mapMap
Discussion
Institution · Lentigen Technology (United States)

Most cited papers from Lentigen Technology (United States)

Lentigen Technology (United States)

What are the most cited papers from Lentigen Technology (United States)?

The most cited paper from Lentigen Technology (United States) is "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy" (Terry J. Fry et al., 2017), with 1,367 citations. Next come "Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial" (469) and "A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines" (265).

Showing 50 of 60 papers. Every paper with more than 11 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy Terry J. Fry et al. · Nature Medicine Open access 20 Nov 2017 1,367
2 Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial Nirav Niranjan Shah, Bryon D. Johnson, Dina Schneider et al. · Nature Medicine Oct 2020 469
3 A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines Dina Schneider, Ying Xiong, Darong Wu et al. · Journal for ImmunoTherapy of Cancer Open access 8 May 2017 265
4 Towards a commercial process for the manufacture of genetically modified T cells for therapy A. Kaiser, Mario Assenmacher, Bernd Schröder et al. · Cancer Gene Therapy Open access 23 Jan 2015 205
5 CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR Haneen Shalabi et al. · Blood Open access 23 May 2022 180
6 Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model Kim Anthony-Gonda, Ariola Bardhi, Alex K. Ray et al. · Science Translational Medicine Open access 7 Aug 2019 165
7 Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice Dan Li et al. · Gastroenterology Open access 12 Feb 2020 164
8 Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models Dina Schneider, Ying Xiong, Darong Wu et al. · Science Translational Medicine 24 Mar 2021 150
9 Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma Paolo Fabrizio Caimi, Gabriela Pacheco Sánchez, Ashish Sharma et al. · Frontiers in Immunology Open access 12 Oct 2021 122
10 Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center Fenlu Zhu, Nirav Niranjan Shah, Huiqing Xu et al. · Cytotherapy 26 Dec 2017 120
11 Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia Nawid Albinger, Rita Pfeifer, Marcus Nitsche et al. · Blood Cancer Journal Open access 13 Apr 2022 114
12 Current status of gene therapy strategies to treat HIV/AIDS David S. Strayer, Ramesh Akkina, Bruce Alan Bunnell et al. · Molecular Therapy Open access 15 Mar 2005 107
13 Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma Zachary Jackson et al. · Frontiers in Immunology Open access 7 Aug 2020 102
14 Lentiviral Vectors: Their Molecular Design, Safety, and Use in Laboratory and Preclinical Research Boro Dropulić · Human Gene Therapy 12 Apr 2011 99
15 Beneficial Effect of β-Mannanase Feed Enzyme on Performance of Chicks Challenged with Eimeria sp. and Clostridium perfringens Mark Jackson, D. M. Anderson, H. Y. Hsiao et al. · Avian Diseases Jul 2003 96
16 Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV Pablo Tebas et al. · Blood Open access 22 Dec 2012 91
17 A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy Rafijul Bari, Markus Granzin, Kam Sze Tsang et al. · Frontiers in Immunology Open access 22 Aug 2019 88
18 Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India Hamenth Kumar Palani, Arun Kumar Arunachalam, Mohammed Yasar et al. · Bone Marrow Transplantation 8 Nov 2022 87
19 Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients Michael A Maschan et al. · Nature Communications Open access 10 Dec 2021 85
20 Generation of a packaging cell line for prolonged large‐scale production of high‐titer HIV‐1‐based lentiviral vector Yajin Ni, Susan Y. Sun, Ibe Oparaocha et al. · The Journal of Gene Medicine 3 Feb 2005 77
21 Cell entry and release of quasi-enveloped human hepatitis viruses Anshuman Das, Efraín E. Rivera-Serrano, Xin Yin et al. · Nature Reviews Microbiology ReviewOpen access 25 Apr 2023 65
22 Cancer cell survival depends on collagen uptake into tumor-associated stroma Kuo-Sheng Hsu et al. · Nature Communications Open access 18 Nov 2022 63
23 Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β Leah M. Alabanza, Ying Xiong, Bang K. Vu et al. · Frontiers in Immunology Open access 8 Feb 2022 59
24 Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII H. Trent Spencer, Gabriela Denning, Richard E. Gautney et al. · Molecular Therapy Open access 16 Nov 2010 59
25 Anomalous X-ray diffraction studies of ion transport in K+ channels Patricia S. Langan, Venu Gopal Vandavasi, Kevin L. Weiss et al. · Nature Communications Open access 25 Oct 2018 58
26 Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells Tamson V. Moore et al. · Cancer Immunology Immunotherapy Open access 20 Oct 2017 50
27 In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells Kim Anthony-Gonda et al. · JCI Insight Open access 7 Nov 2022 48
28 A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia Dina Schneider, Ying Xiong, Peirong Hu et al. · Frontiers in Oncology Open access 22 Nov 2018 47
29 CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting Håkan Norell, Yi Zhang, James McCracken et al. · Cancer Immunology Immunotherapy Open access 5 Jan 2010 44
30 Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models BRIAN R. WEBSTER, Ying Xiong, Peirong Hu et al. · Molecular Therapy Open access 8 May 2021 33
31 Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells Barbara S. Paugh, Lajos Baranyi, Andre J Roy et al. · Scientific Reports Open access 11 Jan 2021 31
32 Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome Boro Dropulić, Carl H. June · Human Gene Therapy Jun 2006 29
33 Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma Meijie Tian et al. · Cell Reports Medicine Open access 28 Sep 2023 27
34 Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1 Tri Minh Tran, Bal Krishna Chand Thakuri, Saule T. Nurmukhambetova et al. · Journal for ImmunoTherapy of Cancer Open access Apr 2024 26
35 CAR-T Cell Production Using the Clinimacs® Prodigy System Fenlu Zhu, Nirav Niranjan Shah, Huiqing Xu et al. · Blood 2 Dec 2016 24
36 Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection Séverine Loisel‐Meyer, Tania C. Felizardo, Jacopo Mariotti et al. · Molecular Cancer Therapeutics Open access Mar 2009 24
37 Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells Nayanendu Saha, Kai Y. Xu, Zhongyu Zhu et al. · Translational Oncology Open access 9 Nov 2021 23
38 Exosomes originating from infection with the cytoplasmic single-stranded RNA virus Rift Valley fever virus (RVFV) protect recipient cells by inducing RIG-I mediated IFN-B response that leads to activation of autophagy Farhang Alem, Adeyemi A. Olanrewaju, Samson Omole et al. · Cell & Bioscience Open access 25 Dec 2021 21
39 Paired Expression Analysis of Tumor Cell Surface Antigens Rimas J. Orentas, Sivasish Sindiri, Christine B. Duris et al. · Frontiers in Oncology Open access 21 Aug 2017 21
40 Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma Djordje Atanackovic et al. · Nature Communications Open access 3 Jul 2025 19
41 AG‐1031 induced autophagic cell death and apoptosis in C6 glioma cells associated with Notch‐1 signaling pathway Yan Wang, Hui Wang, Hui Ming Ge et al. · Journal of Cellular Biochemistry 25 Mar 2018 18
42 Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma Nirav Niranjan Shah, Alfredo Colina, Bryon D. Johnson et al. · Journal of Clinical Oncology 31 Mar 2025 16
43 Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy Jennifer M. Knight, Anikó Szabó, Igli Arapi et al. · Communications Medicine Open access 12 May 2022 16
44 Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors Bettina Kotter, Fabian Engert, Winfried H. Krueger et al. · Cancers Open access 22 Sep 2021 16
45 Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies Joanna C. Zurko, Huiqing Xu, Katherine E. Chaney et al. · Cytotherapy 18 May 2022 15
46 Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells. Boro Dropulić · PubMed Jul 2005 15
47 Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL Berta González‐Martínez et al. · EBioMedicine Open access Aug 2025 14
48 CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity Paolo Fabrizio Caimi, Ashish Sharma, Patricio Rojas et al. · Blood 5 Nov 2020 14
49 Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy Nausheen Ahmed et al. · Transplantation and Cellular Therapy Open access 23 Jan 2020 14
50 Healthcare Antibiotic Resistance Prevalence – DC (HARP-DC): A Regional Prevalence Assessment of Carbapenem-Resistant Enterobacteriaceae (CRE) in Healthcare Facilities in Washington, District of Columbia Jacqueline Reuben et al. · Infection Control and Hospital Epidemiology 15 Jun 2017 14

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.